Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease

Rheumatology (United Kingdom)

Volumn 58, Issue 4, 2019, Pages 567-579

  Khanna, Dinesh ^a   Tashkin, Donald P ^b   Denton, Christopher P ^c   Lubell, Martin W ^d   Vazquez Mateo, Cristina ^d   Wax, Stephen ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d EMD SERONO INC   (United States)

Author keywords

abituzumab; bortezomib; dabigatran; interstitial lung disease; nintedanib; pirfenidone; pulmonary fibrosis; study design; systemic sclerosis

Indexed keywords

ABITUZUMAB; AZATHIOPRINE; BORTEZOMIB; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DABIGATRAN; MYCOPHENOLATE MOFETIL; NINTEDANIB; PIRFENIDONE; POMALIDOMIDE; RITUXIMAB; IMMUNOLOGIC FACTOR;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; HEALTH CARE NEED; HUMAN; INTERSTITIAL LUNG DISEASE; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS; COMPLICATION;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; LUNG DISEASES, INTERSTITIAL; SCLERODERMA, SYSTEMIC;

EID: 85063713665     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/key151     Document Type: Review

References (79)

1. Denton CP, Khanna D. Systemic sclerosis. Lancet 2017;390:1685-99.
2. Fuschiotti P. Current perspectives on the immunopathogenesis of systemic sclerosis. Immunotargets Ther 2016;5:21-35.
3. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
4. Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. Am Fam Physician 2008;78:961-8.
5. Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
6. Nihtyanova SI, Tang EC, Coghlan JG et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010;103:109-15.
7. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010;39:269-77.
8. Shreiner AB, Murray C, Denton C, Khanna D. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord 2016;1:247-56.
9. Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology 2009;48(Suppl 3):iii40-4.
10. Solomon JJ, Olson AL, Fischer A et al. Scleroderma lung disease. Eur Respir Rev 2013;22:6-19.
11. Silver KC, Silver RM. Management of systemic-sclerosisassociated interstitial lung disease. Rheum Dis Clin North Am 2015;41:439-57.
12. Cappelli S, Bellando Randone S, Camiciottoli G et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev 2015;24:411-9.
13. Steen V, Chou M, Shanmugam V et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest 2008;134:146-51.
14. Khanna D, Mittoo S, Aggarwal R et al. Connective tissue disease-associated interstitial lung diseases (CTDILD)- report from OMERACT CTD-ILD Working Group. J Rheumatol 2015;42:2168-71.
15. Goh NS, Hoyles RK, Denton CP et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017;69:1670-8.
16. Yasuoka H. Recent treatments of interstitial lung disease with systemic sclerosis. Clin Med Insights Circ Respir Pulm Med 2015;9(Suppl 1):97-110.
17. Baxter Healthcare. Cyclophosphamide. Prescribing Information. 2013 https://www.accessdata.fda.gov/drugsatfda-docs/label/2013/012141s090,012142s112lbl.pdf (25 May 2018, date last accessed).
18. Omair MA, Alahmadi A, Johnson SR. Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. PLoS One 2015;10:e0124205.
19. Namas R, Tashkin DP, Furst DE et al. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II. Arthritis Care Res 2018;70:439-44.
20. Chighizola C, Ong VH, Denton CP. Cyclophosphamide as disease-modifying therapy for scleroderma: pros and cons. Int J Clin Rheumatol 2011;6:219-30.
21. Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep 2009;11:111-9.
22. Volkmann ER, Chung A, Tashkin DP. Managing systemic sclerosis-related interstitial lung disease in the modern treatment era. J Scleroderma Relat Disord 2017;2:72-83.
23. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
24. Tashkin DP, Elashoff R, Clements PJ et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34.
25. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebocontrolled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
26. Kowal-Bielecka O, Fransen J, Avouac J et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327-39.
27. Tashkin DP, Roth MD, Clements PJ et al. Mycophenolate mofetil versus oral cyclophosphamide in sclerodermarelated interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708-19.
28. Sanford M, Keating GM. Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. Drugs 2008;68:2505-33.
29. Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest 2003;111:1122-4.
30. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006;25:205-12.
31. Helfrich DJ, Banner B, Steen VD, Medsger TA Jr. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989;32:1128-34.
32. DeMarco PJ, Weisman MH, Seibold JR et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983-9.
33. Reichenberger F, Schauer J, Kellner K et al. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001;179:163-74.
34. Seibold JR, Denton CP, Furst DE et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010;62:2101-8.
35. Ferguson GD, Jensen-Pergakes K, Wilkey C et al. Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol 2007;27:210-20.
36. Lacy MQ, McCurdy AR. Pomalidomide. Blood 2013;122:2305-9.
37. Hsu V, Denton CP, Domsic RT et al. A phase 2 study of pomalidomide (CC-4047) to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and effectiveness in subjects with systemic sclerosis with interstitial lung disease. Arthritis Rheumatol 2016;68(Suppl 10):abstract 823.
38. Perosa F, Prete M, Racanelli V, Dammacco F. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 2010;267:260-77.
39. Daoussis D, Liossis SN, Tsamandas AC et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010;49:271-80.
40. Sullivan K, Keyes-Elstein L, McSweeney P et al. Myeloablative autologous transplantation of CD34+-selected hematopoietic stem cells (HSCT) vs monthly intravenous cyclophosphamide (CYC) for severe scleroderma with internal organ involvement: outcomes of a randomized North American clinical trial. Arthritis Rheumatol 2016;68(Suppl S10):abstract 6L.
41. van Laar JM, Farge D, Sont JK et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311:2490-8.
42. Del Papa N, Onida F, Zaccara E et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant 2017;52:53-8.
43. Bell EC, Cox NS, Goh N et al. Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev 2017;26:160080.
44. Ferreira A, Garvey C, Connors GL et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009;135:442-7.
45. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. The Cochrane Database Syst Rev 2014;10:CD006322.
46. Gallagher R. The use of opioids for dyspnea in advanced disease. Can Med Assoc J 2011;183:1170.
47. Miele CH, Schwab K, Saggar R et al. Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience. Ann Am Thorac Soc 2016;13:793-802.
48. Shreiner AB, Murray C, Denton C, Khanna D. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord 2016;1:247-56.
49. Saunders P, Tsipouri V, Keir GJ et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials 2017;18:275.
50. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012;33:405-12.
51. Assoian RK, Schwartz MA. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev 2001;11:48-53.
52. Holly SP, Larson MK, Parise LV. Multiple roles of integrins in cell motility. Exp Cell Res 2000;261:69-74.
53. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
54. Legate KR, Montanez E, Kudlacek O, Fassler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 2006;7:20-31.
55. Nemeth JA, Nakada MT, Trikha M et al. Alpha-v integrins as therapeutic targets in oncology. Cancer Invest 2007;25:632-46.
56. Katsumoto TR, Violette SM, Sheppard D. Blocking TGFb via inhibition of the avb6 integrin: a possible therapy for systemic sclerosis interstitial lung disease. Int J Rheumatol 2011;2011:208219.
57. Horan GS, Wood S, Ona V et al. Partial inhibition of integrin avb6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008;177:56-65.
58. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Increased expression levels of integrin avb5 on scleroderma fibroblasts. Am J Pathol 2004;164:1275-92.
59. Asano Y, Ihn H, Yamane K et al. Increased expression of integrin avb3 contributes to the establishment of autocrine TGF-b signaling in scleroderma fibroblasts. J Immunol 2005;175:7708-18.
60. Uhl W, Zuhlsdorf M, Koernicke T, Forssmann U, Kovar A. Safety, tolerability, and pharmacokinetics of the novel avintegrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. Invest New Drugs 2014;32:347-54.
61. Wirth M, Heidenreich A, Gschwend JE et al. A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting av integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. Eur Urol 2014;65:897-904.
62. Hussain M, Le Moulec S, Gimmi C et al. Differential effect on bone lesions of targeting integrins: randomized phase II trial of abituzumab in patients with metastatic castrationresistant prostate cancer. Clin Cancer Res 2016;22:3192-200.
63. Elez E, Kocakova I, Hohler T et al. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol 2015;26:132-40.
64. Pellom ST Jr, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A. Modulatory effects of bortezomib on host immune cell functions. Immunotherapy 2015;7:1011-22.
65. Mutlu GM, Budinger GR, Wu M et al. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-b1 signalling. Thorax 2012;67:139-46.
66. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011;8:42-54.
67. Sorbera LA, Bozzo J, Castaner J. Dabigatran/dabigatran etexilate. Drugs Future 2005;30:877.
68. Bogatkevich GS, Ludwicka-Bradley A, Silver RM. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum 2009;60:3455-64.
69. Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ et al. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum 2011;63:1416-25.
70. Wollin L, Wex E, Pautsch A et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-45.
71. Distler O, Brown KK, Distler JHW et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS). Clin Exp Rheumatol 2017;35(Suppl 106):75-81.
72. Khanna D, Albera C, Fischer A et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol 2016;43:1672-9.
73. Sakkas LI. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis. Drug Des Devel Ther 2016;10:2723-8.
74. Passalacqua G, Mincarini M, Colombo D et al. IL-13 and idiopathic pulmonary fibrosis: possible links and new therapeutic strategies. Pulm Pharmacol Ther 2017;45:95-100.
75. Kingwell K. InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs. Nat Rev Drug Discov 2014;13:483-4.
76. Khanna D, Seibold J, Goldin J et al. Interstitial lung disease points to consider for clinical trials in systemic sclerosis. Rheumatology 2017;56(Suppl-5):v27-32.
77. Castelino FV, Bain G, Pace VA et al. An autotaxin/lysophosphatidic acid/interleukin-6 amplification loop drives scleroderma fibrosis. Arthritis Rheumatol 2016;68:2964-74.
78. Du J, Paz K, Flynn R et al. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-b production. Blood 2017;129:2570-80.
79. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-23.